
Microbiome Therapeutics Industry Research Report 2025
Description
Summary
The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).
These microbes are generally not harmful to us; in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.
An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.
According to APO Research, The global Microbiome Therapeutics market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Microbiome Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Microbiome Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Microbiome Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Microbiome Therapeutics include Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon, PureTech, Synlogic, Enterome BioScience, 4D Pharma and Second Genome, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Microbiome Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Microbiome Therapeutics.
The Microbiome Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Microbiome Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Microbiome Therapeutics Segment by Company
Seres Therapeutics
Assembly Biosciences
Synthetic Biologics
Interxon
PureTech
Synlogic
Enterome BioScience
4D Pharma
Second Genome
AOBiome
C3 Jian
Rebiotix
MicroBiome Therapeutics LLC
Metabiomics
Ritter Pharmaceuticals
Symberix
OpenBiome
Azitra
Symbiotix Biotherapies
Osel
Metabogen
Microbiome Therapeutics Segment by Type
Upper GIT
Lower GIT
Microbiome Therapeutics Segment by Application
C. difficile Infection (CDI)
Inflammatory Bowel Disease (IBD)
Orphan Drug
Immuno-oncology
Others
Microbiome Therapeutics Segment by Application
C. difficile Infection (CDI)
Inflammatory Bowel Disease (IBD)
Orphan Drug
Immuno-oncology
Others
Microbiome Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbiome Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Microbiome Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbiome Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Microbiome Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).
These microbes are generally not harmful to us; in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.
An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.
According to APO Research, The global Microbiome Therapeutics market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Microbiome Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Microbiome Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Microbiome Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Microbiome Therapeutics include Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon, PureTech, Synlogic, Enterome BioScience, 4D Pharma and Second Genome, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Microbiome Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Microbiome Therapeutics.
The Microbiome Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Microbiome Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Microbiome Therapeutics Segment by Company
Seres Therapeutics
Assembly Biosciences
Synthetic Biologics
Interxon
PureTech
Synlogic
Enterome BioScience
4D Pharma
Second Genome
AOBiome
C3 Jian
Rebiotix
MicroBiome Therapeutics LLC
Metabiomics
Ritter Pharmaceuticals
Symberix
OpenBiome
Azitra
Symbiotix Biotherapies
Osel
Metabogen
Microbiome Therapeutics Segment by Type
Upper GIT
Lower GIT
Microbiome Therapeutics Segment by Application
C. difficile Infection (CDI)
Inflammatory Bowel Disease (IBD)
Orphan Drug
Immuno-oncology
Others
Microbiome Therapeutics Segment by Application
C. difficile Infection (CDI)
Inflammatory Bowel Disease (IBD)
Orphan Drug
Immuno-oncology
Others
Microbiome Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbiome Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Microbiome Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbiome Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Microbiome Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
146 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Microbiome Therapeutics by Type
- 2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
- 2.2.2 Upper GIT
- 2.2.3 Lower GIT
- 2.3 Microbiome Therapeutics by Application
- 2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.3.2 C. difficile Infection (CDI)
- 2.3.3 Inflammatory Bowel Disease (IBD)
- 2.3.4 Orphan Drug
- 2.3.5 Immuno-oncology
- 2.3.6 Others
- 2.4 Assumptions and Limitations
- 3 Microbiome Therapeutics Breakdown Data by Type
- 3.1 Global Microbiome Therapeutics Historic Market Size by Type (2020-2025)
- 3.2 Global Microbiome Therapeutics Forecasted Market Size by Type (2026-2031)
- 4 Microbiome Therapeutics Breakdown Data by Application
- 4.1 Global Microbiome Therapeutics Historic Market Size by Application (2020-2025)
- 4.2 Global Microbiome Therapeutics Forecasted Market Size by Application (2026-2031)
- 5 Global Growth Trends
- 5.1 Global Microbiome Therapeutics Market Perspective (2020-2031)
- 5.2 Global Microbiome Therapeutics Growth Trends by Region
- 5.2.1 Global Microbiome Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
- 5.2.2 Microbiome Therapeutics Historic Market Size by Region (2020-2025)
- 5.2.3 Microbiome Therapeutics Forecasted Market Size by Region (2026-2031)
- 5.3 Microbiome Therapeutics Market Dynamics
- 5.3.1 Microbiome Therapeutics Industry Trends
- 5.3.2 Microbiome Therapeutics Market Drivers
- 5.3.3 Microbiome Therapeutics Market Challenges
- 5.3.4 Microbiome Therapeutics Market Restraints
- 6 Market Competitive Landscape by Players
- 6.1 Global Top Microbiome Therapeutics Players by Revenue
- 6.1.1 Global Top Microbiome Therapeutics Players by Revenue (2020-2025)
- 6.1.2 Global Microbiome Therapeutics Revenue Market Share by Players (2020-2025)
- 6.2 Global Microbiome Therapeutics Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Microbiome Therapeutics Head Office and Area Served
- 6.4 Global Microbiome Therapeutics Players, Product Type & Application
- 6.5 Global Microbiome Therapeutics Manufacturers Established Date
- 6.6 Global Microbiome Therapeutics Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
- 7 North America
- 7.1 North America Microbiome Therapeutics Market Size (2020-2031)
- 7.2 North America Microbiome Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 7.3 North America Microbiome Therapeutics Market Size by Country (2020-2025)
- 7.4 North America Microbiome Therapeutics Market Size by Country (2026-2031)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
- 8 Europe
- 8.1 Europe Microbiome Therapeutics Market Size (2020-2031)
- 8.2 Europe Microbiome Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 8.3 Europe Microbiome Therapeutics Market Size by Country (2020-2025)
- 8.4 Europe Microbiome Therapeutics Market Size by Country (2026-2031)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
- 9 Asia-Pacific
- 9.1 Asia-Pacific Microbiome Therapeutics Market Size (2020-2031)
- 9.2 Asia-Pacific Microbiome Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 9.3 Asia-Pacific Microbiome Therapeutics Market Size by Country (2020-2025)
- 9.4 Asia-Pacific Microbiome Therapeutics Market Size by Country (2026-2031)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
- 10 South America
- 10.1 South America Microbiome Therapeutics Market Size (2020-2031)
- 10.2 South America Microbiome Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 10.3 South America Microbiome Therapeutics Market Size by Country (2020-2025)
- 10.4 South America Microbiome Therapeutics Market Size by Country (2026-2031)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
- 11 Middle East & Africa
- 11.1 Middle East & Africa Microbiome Therapeutics Market Size (2020-2031)
- 11.2 Middle East & Africa Microbiome Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 11.3 Middle East & Africa Microbiome Therapeutics Market Size by Country (2020-2025)
- 11.4 Middle East & Africa Microbiome Therapeutics Market Size by Country (2026-2031)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
- 12 Players Profiled
- 12.1 Seres Therapeutics
- 12.1.1 Seres Therapeutics Company Information
- 12.1.2 Seres Therapeutics Business Overview
- 12.1.3 Seres Therapeutics Revenue in Microbiome Therapeutics Business (2020-2025)
- 12.1.4 Seres Therapeutics Microbiome Therapeutics Product Portfolio
- 12.1.5 Seres Therapeutics Recent Developments
- 12.2 Assembly Biosciences
- 12.2.1 Assembly Biosciences Company Information
- 12.2.2 Assembly Biosciences Business Overview
- 12.2.3 Assembly Biosciences Revenue in Microbiome Therapeutics Business (2020-2025)
- 12.2.4 Assembly Biosciences Microbiome Therapeutics Product Portfolio
- 12.2.5 Assembly Biosciences Recent Developments
- 12.3 Synthetic Biologics
- 12.3.1 Synthetic Biologics Company Information
- 12.3.2 Synthetic Biologics Business Overview
- 12.3.3 Synthetic Biologics Revenue in Microbiome Therapeutics Business (2020-2025)
- 12.3.4 Synthetic Biologics Microbiome Therapeutics Product Portfolio
- 12.3.5 Synthetic Biologics Recent Developments
- 12.4 Interxon
- 12.4.1 Interxon Company Information
- 12.4.2 Interxon Business Overview
- 12.4.3 Interxon Revenue in Microbiome Therapeutics Business (2020-2025)
- 12.4.4 Interxon Microbiome Therapeutics Product Portfolio
- 12.4.5 Interxon Recent Developments
- 12.5 PureTech
- 12.5.1 PureTech Company Information
- 12.5.2 PureTech Business Overview
- 12.5.3 PureTech Revenue in Microbiome Therapeutics Business (2020-2025)
- 12.5.4 PureTech Microbiome Therapeutics Product Portfolio
- 12.5.5 PureTech Recent Developments
- 12.6 Synlogic
- 12.6.1 Synlogic Company Information
- 12.6.2 Synlogic Business Overview
- 12.6.3 Synlogic Revenue in Microbiome Therapeutics Business (2020-2025)
- 12.6.4 Synlogic Microbiome Therapeutics Product Portfolio
- 12.6.5 Synlogic Recent Developments
- 12.7 Enterome BioScience
- 12.7.1 Enterome BioScience Company Information
- 12.7.2 Enterome BioScience Business Overview
- 12.7.3 Enterome BioScience Revenue in Microbiome Therapeutics Business (2020-2025)
- 12.7.4 Enterome BioScience Microbiome Therapeutics Product Portfolio
- 12.7.5 Enterome BioScience Recent Developments
- 12.8 4D Pharma
- 12.8.1 4D Pharma Company Information
- 12.8.2 4D Pharma Business Overview
- 12.8.3 4D Pharma Revenue in Microbiome Therapeutics Business (2020-2025)
- 12.8.4 4D Pharma Microbiome Therapeutics Product Portfolio
- 12.8.5 4D Pharma Recent Developments
- 12.9 Second Genome
- 12.9.1 Second Genome Company Information
- 12.9.2 Second Genome Business Overview
- 12.9.3 Second Genome Revenue in Microbiome Therapeutics Business (2020-2025)
- 12.9.4 Second Genome Microbiome Therapeutics Product Portfolio
- 12.9.5 Second Genome Recent Developments
- 12.10 AOBiome
- 12.10.1 AOBiome Company Information
- 12.10.2 AOBiome Business Overview
- 12.10.3 AOBiome Revenue in Microbiome Therapeutics Business (2020-2025)
- 12.10.4 AOBiome Microbiome Therapeutics Product Portfolio
- 12.10.5 AOBiome Recent Developments
- 12.11 C3 Jian
- 12.11.1 C3 Jian Company Information
- 12.11.2 C3 Jian Business Overview
- 12.11.3 C3 Jian Revenue in Microbiome Therapeutics Business (2020-2025)
- 12.11.4 C3 Jian Microbiome Therapeutics Product Portfolio
- 12.11.5 C3 Jian Recent Developments
- 12.12 Rebiotix
- 12.12.1 Rebiotix Company Information
- 12.12.2 Rebiotix Business Overview
- 12.12.3 Rebiotix Revenue in Microbiome Therapeutics Business (2020-2025)
- 12.12.4 Rebiotix Microbiome Therapeutics Product Portfolio
- 12.12.5 Rebiotix Recent Developments
- 12.13 MicroBiome Therapeutics LLC
- 12.13.1 MicroBiome Therapeutics LLC Company Information
- 12.13.2 MicroBiome Therapeutics LLC Business Overview
- 12.13.3 MicroBiome Therapeutics LLC Revenue in Microbiome Therapeutics Business (2020-2025)
- 12.13.4 MicroBiome Therapeutics LLC Microbiome Therapeutics Product Portfolio
- 12.13.5 MicroBiome Therapeutics LLC Recent Developments
- 12.14 Metabiomics
- 12.14.1 Metabiomics Company Information
- 12.14.2 Metabiomics Business Overview
- 12.14.3 Metabiomics Revenue in Microbiome Therapeutics Business (2020-2025)
- 12.14.4 Metabiomics Microbiome Therapeutics Product Portfolio
- 12.14.5 Metabiomics Recent Developments
- 12.15 Ritter Pharmaceuticals
- 12.15.1 Ritter Pharmaceuticals Company Information
- 12.15.2 Ritter Pharmaceuticals Business Overview
- 12.15.3 Ritter Pharmaceuticals Revenue in Microbiome Therapeutics Business (2020-2025)
- 12.15.4 Ritter Pharmaceuticals Microbiome Therapeutics Product Portfolio
- 12.15.5 Ritter Pharmaceuticals Recent Developments
- 12.16 Symberix
- 12.16.1 Symberix Company Information
- 12.16.2 Symberix Business Overview
- 12.16.3 Symberix Revenue in Microbiome Therapeutics Business (2020-2025)
- 12.16.4 Symberix Microbiome Therapeutics Product Portfolio
- 12.16.5 Symberix Recent Developments
- 12.17 OpenBiome
- 12.17.1 OpenBiome Company Information
- 12.17.2 OpenBiome Business Overview
- 12.17.3 OpenBiome Revenue in Microbiome Therapeutics Business (2020-2025)
- 12.17.4 OpenBiome Microbiome Therapeutics Product Portfolio
- 12.17.5 OpenBiome Recent Developments
- 12.18 Azitra
- 12.18.1 Azitra Company Information
- 12.18.2 Azitra Business Overview
- 12.18.3 Azitra Revenue in Microbiome Therapeutics Business (2020-2025)
- 12.18.4 Azitra Microbiome Therapeutics Product Portfolio
- 12.18.5 Azitra Recent Developments
- 12.19 Symbiotix Biotherapies
- 12.19.1 Symbiotix Biotherapies Company Information
- 12.19.2 Symbiotix Biotherapies Business Overview
- 12.19.3 Symbiotix Biotherapies Revenue in Microbiome Therapeutics Business (2020-2025)
- 12.19.4 Symbiotix Biotherapies Microbiome Therapeutics Product Portfolio
- 12.19.5 Symbiotix Biotherapies Recent Developments
- 12.20 Osel
- 12.20.1 Osel Company Information
- 12.20.2 Osel Business Overview
- 12.20.3 Osel Revenue in Microbiome Therapeutics Business (2020-2025)
- 12.20.4 Osel Microbiome Therapeutics Product Portfolio
- 12.20.5 Osel Recent Developments
- 12.21 Metabogen
- 12.21.1 Metabogen Company Information
- 12.21.2 Metabogen Business Overview
- 12.21.3 Metabogen Revenue in Microbiome Therapeutics Business (2020-2025)
- 12.21.4 Metabogen Microbiome Therapeutics Product Portfolio
- 12.21.5 Metabogen Recent Developments
- 13 Report Conclusion
- 14 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.